

**MICHAEL MAIR, MPH**

**Business Address:**

Food and Drug Administration  
US Department of Health and Human Services



**Home Address:**



---

---

**PROFESSIONAL EXPERIENCE**

**Policy Analysis & Research**

**Office of Counterterrorism and Emerging Threats, Office of the Chief Scientist, Food and Drug Administration, US Department of Health and Human Services**  
—Silver Spring, MD

October 2012-  
Present

**Director of Strategic Operations**

- Primary duties and responsibilities include supporting the FDA Assistant Commissioner for Counterterrorism and Emerging Threats and the FDA Office of Counterterrorism and Emerging Threats (OCET) in: (1) initiating, directing, and implementing a comprehensive range of activities to support OCET and the Medical Countermeasures Initiative (MCMi) including policy development and implementation, project management and support, program tracking and reporting, communications and stakeholder engagement, information flow, OCET/MCMi annual budget formulation, and organizational development and assessment; and (2) managing staff in the OCET Division of Strategic Operations.

**Office of the Chief Scientist, Food and Drug Administration, US Department of Health and Human Services**—Silver Spring, MD

January 2011-  
Present

**Senior Policy Analyst**

- Primary duties and responsibilities include supporting the FDA Assistant Commissioner for Counterterrorism and Emerging Threats and the FDA Office of Counterterrorism and Emerging Threats (OCET) in: (1) the development, analysis, interpretation, and evaluation of relevant scientific and regulatory issues, laws, policies and regulations; (2) developing policy and programmatic goals and objectives for OCET (including for the MCMi) and implementing projects to meet those goals and objectives; (3) managing program objectives to ensure programs are consistent with goals and objectives; (4) monitoring program development to ensure that timelines are met; (5) communicating OCET/MCMi program accomplishments within FDA and with external stakeholders; (6) representing OCET (verbally and/or in writing) within FDA and with external stakeholders including other HHS OPDIVS, US government agencies, and non-government entities including serving as FDA liaison to the PHEMCE; and (7) supporting the FDA Office of Budget in the development of the OCET/MCMi annual budget formulation.

**Division of Medical Countermeasure Strategy and Requirements, Office of Policy and Planning (OPP), Office of the Assistant Secretary for Preparedness and Response (ASPR), US Department of Health and Human Services**—Washington, DC  
**Policy Analyst, Acting PHEMCE Branch Chief (March – December 2010)**

July 2009-  
December 2010

- Primary duties and responsibilities include supporting the Office of Policy and Planning in: (1) the analysis of proposed policies, Presidential Directives, and regulations; (2) developing short- and long-term policy objectives for ASPR; (3) managing strategic planning program objectives to ensure programs are consistent with ASPR goals; (4) monitoring program development to ensure that timelines are

met; and (5) supporting PHEMCE medical countermeasure policy analysis, development, and oversight.

**Center for Biosecurity, University of Pittsburgh Medical Center—Baltimore, MD**  
**Associate**

September 2006-  
June 2009

- Primary duties and responsibilities include: (1) producing original work in field of expertise; (2) engaging in strategic planning; (3) designing, initiating, executing, and managing projects (as project manager or team member); (4) maintaining a high level of awareness and expertise in biodefense policy and technical issues and developments; (5) representing the Center and, where necessary, organizing networks and facilitating communications in the biodefense, national security, public health, medical, governance and policy communities; (6) engaging in public and community outreach, including interaction with the media; and (7) helping to develop and coach less-experienced staff.
- Project manager on effort to reduce building occupants' risk of exposure to biological threats.
- Research focus areas include medical countermeasure development, medical diplomacy, and pandemic influenza preparedness.

**Center for Biosecurity, University of Pittsburgh Medical Center—Baltimore, MD**  
**Senior Analyst**

November 2003–  
September 2006

- Primary duties and responsibilities include: (1) coordinating the work of the Analysts as they respond to Center requests for research and policy analysis; (2) coordinating the provision of information and analysis to all Center staff; (3) serving as a member, and at times, project manager of project teams; (4) producing original work in field(s) of expertise; (5) participating in the national and international dialogue on biosecurity issues through publication, presentations, and professional interactions; (6) participating in Center strategic planning; and (7) mentoring, supporting, and providing direction to junior staff.

**Center for Civilian Biodefense Strategies**  
**Johns Hopkins University Bloomberg School of Public Health—Baltimore, MD**  
**Senior Research Assistant**

June 2001–  
October 2003

- Job description the same as above for Senior Analyst position at the Center for Biosecurity.

**Biomedical Research**

**National Cancer Institute, NIH—Bethesda, MD**  
**Biologist – Lab of Pathology, Division of Clinical Sciences, Woman's Cancers Section**

Aug 1998 –  
May 2001

- Breast Cancer Research—develop, enhance, and apply a variety of complex biochemical procedures, recombinant DNA methodologies, and biochemical and biological assays to foster an understanding of the molecular mechanisms of breast cancer malignant progression with the goal of preventing metastatic disease.
- Training—serve as a resource and technical advisor to post-doctoral/MD fellows and technical staff.
- Laboratory Management—responsible for general administration.

**Temple University—Philadelphia, PA**  
**Senior Research Technician – Division of Infectious Diseases**

July 1994 -  
July 1998

- Infectious Disease Research—develop and apply a variety of complex molecular biological techniques to investigate and track the spread of infectious diseases in the hospital setting; detect various pathogens on a molecular level; and detect and characterize genes for antimicrobial resistance.

- Training—serve as a resource and technical advisor to post-doctoral/MD fellows and technical staff.
- Laboratory Management—responsible for general administration.

**Cooper Hospital/University Medical Center**—Camden, NJ Nov. 1991 -  
**Research Technician – Division of Infectious Diseases** June 1994

- Job description same as above for Temple University.

**Coriell Institute for Medical Research**—Camden, NJ June 1990 -  
**Research Technician** Nov. 1991

- Perform PCR analyses on lymphoblastoid cell line extracts to detect the presence of nucleotide sequences specific to HIV-I.

## PROFESSIONAL ACTIVITIES

### Consulting

- 1) Served as an advisor to the Baltimore City Health Department in 2003-04 on bioterrorism preparedness issues including:
  - Design and implementation of city-wide, operational bioterrorism exercises
  - Training Baltimore City Health, and Fire Department personnel on biological threats
  - Training Baltimore City Health and Police Department personnel who are part of smallpox response teams on the forensic epidemiological investigation of bioterrorism attacks

## EDITORIAL ACTIVITIES

- 1) Managing Editor for the *Biosecurity Briefing*, Center for Civilian Biodefense Strategies and Center for Biosecurity, UPMC (2001-06)
- 2) Associate editor for *Biosecurity and Bioterrorism: Biodefense Strategy, Practice and Science*, Mary Ann Liebert, Inc. (2003-2009)
- 3) Section Editor for *Highlights & Happenings* section of *Biosecurity and Bioterrorism: Biodefense Strategy, Practice and Science*, Mary Ann Liebert, Inc. (2005-2009)
- 4) Consulting editor for *Bioterrorism and Public Health: An Internet Resource Guide*, eMedguides.com, Thompson Medical Economics (2002)

## EDUCATION

**Bloomberg School of Public Health, Johns Hopkins University**—Baltimore, MD 2001 – 2003

- Master of Public Health
- Certificate in Vaccine Science and Policy
- Delta Omega Society, Alpha Chapter—National Public Health Honorary Society

**Juniata College** –Huntington, PA 1986 - 1988

- Bachelor of Science—Degree in Molecular Biology 1989 - 1990

**Humberside College of Higher Education**—Hull, England 1988 - 1989

- Exchange Program from Juniata College

## PUBLICATIONS


- 1) Matheny J, Smith, B, Courtney, B, **Mair, M.** Drug and Vaccine Development for Infectious Diseases: The Value of Priority Review Vouchers. *Clinical Pharmacology & Therapeutics*. 2009 Jun; 85(6):571-2. Available at <http://www.nature.com/clpt/journal/v85/n6/pdf/clpt200953a.pdf>

- 2) Matheny J, **Mair M**, Smith B. Cost/success projections for US biodefense countermeasure development. *Nature Biotechnology*. 2008 Sep; 26(9):981-3. Available at <http://www.nature.com/nbt/journal/v26/n9/pdf/nbt0908-981.pdf>.
- 3) Matheny J, **Mair M**, Mulcahy A, and Smith BT. Incentives for Biodefense Countermeasure Development. *Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science*. 5(3): 228-38, 2007. Available at [http://www.upmc-biosecurity.org/website/resources/publications/2007\\_orig-articles/2007\\_article\\_pdfs/2007-09-15-incentivesbiodefensecountermeasure.pdf](http://www.upmc-biosecurity.org/website/resources/publications/2007_orig-articles/2007_article_pdfs/2007-09-15-incentivesbiodefensecountermeasure.pdf).
- 4) Gronvall GK, Matheny J, Smith BT, **Mair M**, Chamberlain A, Deitch S, Borio L, Inglesby TV, and O'Toole T. Flexible Defenses Roundtable Meeting: Promoting the Strategic Innovation of Medical Countermeasures. *Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science*. 5(3): 271-77, 2007. Available at [http://www.upmc-biosecurity.org/website/resources/publications/2007\\_orig-articles/2007\\_article\\_pdfs/2007-09-15-flexibledefensesroundtablemeeting.pdf](http://www.upmc-biosecurity.org/website/resources/publications/2007_orig-articles/2007_article_pdfs/2007-09-15-flexibledefensesroundtablemeeting.pdf).
- 5) Gronvall GK, Smith BT, Matheny J, **Mair M**, Chamberlain A, Deitch S, Borio L, Inglesby TV, and O'Toole. Biomedical Advanced Research and Development Authority (BARDA) Roundtable. T. *Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science*. 5(2): 174-79, 2007. Available at [http://www.upmc-biosecurity.org/website/resources/publications/2007\\_orig-articles/2007\\_article\\_pdfs/2007-07-03-bardameetingreport.pdf](http://www.upmc-biosecurity.org/website/resources/publications/2007_orig-articles/2007_article_pdfs/2007-07-03-bardameetingreport.pdf)
- 6) **Mair, M**. Grow, R.W., Mair, J.S., Radonovich, L.J. Universal Influenza Vaccination: The Time to Act Is Now. *Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science*, 4(1): 20-40, 2006. Available at [http://www.upmc-biosecurity.org/website/resources/publications/2006\\_orig-articles/2006\\_article\\_pdfs/2006-03-15-universalfuvaccination.pdf](http://www.upmc-biosecurity.org/website/resources/publications/2006_orig-articles/2006_article_pdfs/2006-03-15-universalfuvaccination.pdf).
- 7) Hitchcock, P.J. **Mair, M**. Inglesby, T.V. Gross, J. D. Henderson, D.A. O'toole, T. Ahern-Seronde, J. Bahnfleth, W.P. Brennan, T. Burroughs, H.E.B. Davidson, C. Delp, W. Ensor, D. Gomory, R. Olsiewski, P. Samet, J.M. Smith, W.M. Streifel, A.J. White, R.H. Woods. Improving Performance of HVAC Systems to Reduce Exposure to Aerosolized Infectious Agents in Buildings; Recommendations to Reduce Risks Posed by Biological Attacks. *Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science*, 4(1): 41-53, 2006. Available at [http://www.upmc-biosecurity.org/website/resources/publications/2006\\_orig-articles/2006\\_article\\_pdfs/2006-03-15-improvingperformanceofhvacsystems.pdf](http://www.upmc-biosecurity.org/website/resources/publications/2006_orig-articles/2006_article_pdfs/2006-03-15-improvingperformanceofhvacsystems.pdf).
- 8) **Mair, M**. Building Security: Biological Weapons Threats, *IAQ Applications*, Spring 2005.
- 9) **Mair M**, Mair JS. A Complementary Approach Bioterrorism Prevention. *Nonproliferation Review*, 10 (3): 114-124, Fall/Winter 2003. Available at <http://cns.mii.edu/npr/pdfs/103mair.pdf>.
- 10) Mair JS, **Mair M**. CPTED and Public Health: A Natural Partnership. *The CPTED Journal*, 2 (1): 21-33, 2003
- 11) Mair JS, **Mair M**. Vaccine Liability in the Era of Bioterrorism. *Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science*, 1(3): 169-184, 2003. Available at [http://www.upmc-biosecurity.org/website/resources/publications/2003\\_orig-articles/2003\\_article\\_pdfs/2003-09-15-vaccineliability.pdf](http://www.upmc-biosecurity.org/website/resources/publications/2003_orig-articles/2003_article_pdfs/2003-09-15-vaccineliability.pdf).
- 12) Bartlett J, Borio L, Radonovich L, O'Toole T, Mair J, Grow R, **Mair M**, Halsey N, Inglesby T. Smallpox Vaccination in 2003: Key Information for Clinicians. *Clinical Infectious Diseases* 36(7):883-902, April 1, 2003. Available at <http://cid.oxfordjournals.org/content/36/7/883.full.pdf+html>.
- 13) **Mair M**, Borio L. Key Information Regarding Smallpox Vaccine. *Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science*, 1(1): 53-54, 2003. Available online at [http://www.upmc-biosecurity.org/website/resources/publications/2003\\_orig-articles/2003\\_article\\_pdfs/2003-03-15-keyinformationresmallpoxvaccine.pdf.pdf](http://www.upmc-biosecurity.org/website/resources/publications/2003_orig-articles/2003_article_pdfs/2003-03-15-keyinformationresmallpoxvaccine.pdf.pdf).

- 14) Mair JS, **Mair M**. Violence Prevention and Control Through Environmental Modifications. *Annual Review of Public Health* 2003; 24:209-25. Available at <http://arjournals.annualreviews.org/doi/abs/10.1146/annurev.publhealth.24.100901.140826>.
- 15) O'Toole T, **Mair M**, Inglesby T. Shining Light on Dark Winter. *Clinical Infectious Diseases* 34, 972-983, April 1, 2002. Available at <http://cid.oxfordjournals.org/content/34/7/972.full.pdf+html>.
- 16) Hartsough MT, Morrison DK, Salerno M, Palmieri D, Ouatas T, **Mair M**, Patrick J, Steeg PS. Nm23-H1 Metastasis Suppressor Phosphorylation of Kinase Suppressor of Ras via a Histidine Protein Kinase Pathway. *Journal of Biological Chemistry* 277, 32389-32399, August 30, 2002. Available at <http://www.jbc.org/cgi/reprint/277/35/32389.pdf>.
- 17) Hartsough MT, Clare SE, **Mair M**, Sgroi D, Osborne K, Clark G, Elkahloun A, Steeg PS. Elevation of Breast Carcinoma Nm23-H1 Metastasis Suppressor Gene Expression and Reduced Motility by DNA Methylation Inhibition. *Cancer Research* 61, 2320-2327, March 1, 2001. Available at <http://cancerres.aacrjournals.org/cgi/reprint/61/5/2320.pdf>
- 18) Steeg PS, Ouatas T, **Mair M**, Clare SE, Hartsough MT. Metastasis Suppressor Genes in Breast Cancer: Nm23. *J. Women's Cancer* 2001.
- 19) Steeg PS, Ouatas T, **Mair M**, Clare SE, Hartsough MT. Nm23 metastasis suppressor gene. In: Welch, D. (Ed.): *Cancer metastasis - Biology and Treatment. Volume IV. Cancer Metastasis-Related Genes*. The Netherlands, Kluwer. Pp 123-144, 2002.
- 20) Kostman JR, Alden MB, **Mair M**, Edlind TD, LIPuma JJ, Stull TL. A Universal Approach to Bacterial Molecular Epidemiology by Polymerase Chain Reaction Ribotyping. *Journal of Infectious Diseases* 1995;171: 204-8.

**Committee on Energy and Commerce**  
**U.S. House of Representatives**  
Witness Disclosure Requirement - "Truth in Testimony"  
Required by House Rule XI, Clause 2(g)(5)

<b>1. Your Name:</b> Michael Mair		
<b>2. Your Title:</b> Director of Strategic Operations		
<b>3. The Entity(ies) You are Representing:</b> U.S. Food and Drug Administration, Office of Counterterrorism and Emerging Threats		
<b>4. Are you testifying on behalf of the Federal, or a State or local government entity?</b>	Yes	No
	X	
<b>5. Please list any Federal grants or contracts, or contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2013. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.</b>  N/A		
<b>6. Please attach your curriculum vitae to your completed disclosure form.</b>		

Signature: 

Date: 05/17/2016